(00:32):

Before we get started, Dr. Dubey, could you just tell us a little about your role in the lab?

(01:33):

Just in case our audience missed it, you're seeing patients Dr. Dubey, right, and spending considerable time in the lab. So really bench to bedside?

(02:11):

Can you just remind the audience what this test is meant to do?

(04:54):

Can you just elaborate on that a little bit and why we think it's not appropriate to search for a catch all type of evaluation?

(07:47):

What are the red flags that would point to this axonal evaluation being appropriate as a next step?

(11:01):

If we order based on axonal or demyelinating, we don't have to compliment that testing with another motor sensory panel is, am I understanding that correctly?

(13:41):

Can you speak to what is still remaining to round out our neuropathy menu? Eventually we'll have a comprehensive evaluation in those cases where the EMG results are also a little unclear, right?

(15:30):

Do you think that physicians can replace Pavel with the axonal evaluation in every case, or are there still sometimes when Pavel or the paraneoplastic evaluation that we've historically offered is more appropriate?

(16:48):

Can you speak to how axonal has taken a lot of the same antibodies, but improved the testing based upon methodology and specificity? What are some of the key changes that we made for axonal?

(20:03):

What are you most excited about and what do you want physicians to take away with the promotion of this axonal auto-immune evaluation?